Bellicum buys into CAR-T manufacturing amid a hot immuno-oncology race

Damian Garde Following the lead of Juno Therapeutics and Kite Pharma, CAR-T contender Bellicum Pharmaceuticals is splashing cash on an in-house manufacturing operation, speeding its ...

Pfizer settles lawsuits tying sex and gambling addictions to dopamine meds

Eric Palmer Pfizer is settling class-action litigation brought by patients who claimed the drugmaker did not adequately warn them of possible side effects of drugs they were taking ...

MorphoSys bags a peptide biotech for $22M

Damian Garde MorphoSys pulled the trigger on a deal for partner Lanthio Pharma, paying €20 million ($ 22 million) for the shares it didn't already own and picking up a handful ...

‘No path forward’ with Teva, Mylan pledges amid warring roadshows

Carly Helfand Late last month, Teva kicked off a roadshow to meet shareholders of its buyout target, Mylan, and find out what price it'll need to put forth to convince them to support ...

BMS looks to Caforio as next CEO

Alok Saboo FierceBiotech News

FDA staffers raise doubts over key Vertex combo

Carly Helfand As an FDA review nears for Vertex's Kalydeco-lumacaftor tandem–approval of which could help Kalydeco reach 10 times the number of cystic fibrosis patients it ...

Oxford BioMedica takes out $50M loan to service Novartis CAR-T alliance

Nick Paul Taylor Oxford BioMedica has secured a $ 50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. ...

Pharma hikes prices on all sorts of meds, but hit diabetes hardest: Bloomberg

Tracy Staton Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years, Bloomberg reports. Once again, the usual suspects ...

Caforio takes CEO role as BMS faces tough year with promising new drugs

Eric Palmer Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today ...

Gilead jumps into epigenetics with a bite-size biotech buyout

Damian Garde As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing ...

Zoetis, under pressure from activist investor Ackman, will offload 10 plants to cut costs

Eric Palmer Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor. FiercePharma News

Symbiomix pops out of stealth mode with $41M and a looming PhIII

John Carroll In the little more than two years since its launch, Symbiomix Therapeutics has successfully navigated a midstage study for a sole-asset antibiotic, positioning it for a ...
Page 4 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS